1. Home
  2. KALA vs HUMA Comparison

KALA vs HUMA Comparison

Compare KALA & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$3.08

Market Cap

172.0M

Sector

Health Care

ML Signal

HOLD

Logo Humacyte Inc.

HUMA

Humacyte Inc.

HOLD

Current Price

$0.94

Market Cap

155.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALA
HUMA
Founded
2009
2004
Country
United States
United States
Employees
N/A
184
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
172.0M
155.4M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
KALA
HUMA
Price
$3.08
$0.94
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$31.50
$6.19
AVG Volume (30 Days)
3.0M
5.8M
Earning Date
04-15-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
67.39
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$444.16
Revenue Next Year
N/A
$248.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.07
$0.55
52 Week High
$20.58
$2.93

Technical Indicators

Market Signals
Indicator
KALA
HUMA
Relative Strength Index (RSI) 76.31 52.96
Support Level $0.32 $0.92
Resistance Level $20.58 $1.30
Average True Range (ATR) 0.21 0.11
MACD 0.34 0.01
Stochastic Oscillator 74.23 39.30

Price Performance

Historical Comparison
KALA
HUMA

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

About HUMA Humacyte Inc.

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: